No open-access location is known for this record yet.
No open-access location is known for this record yet.
Ideas and Opinions15 August 2017The Pharmaceuticalization of the Tobacco IndustryYogi Hale Hendlin, PhD, Jesse Elias, MA, and Pamela M. Ling, MD, MPHYogi Hale Hendlin, PhDFrom the University of California, San Francisco, San Francisco, California., Jesse Elias, MAFrom the University of California, San Francisco, San Francisco, California., and Pamela M. Ling, MD, MPHFrom the University of California, San Francisco, San Francisco, California.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/M17-0759 Annals Author Insight Video - Yogi Hale Hendlin, PhD; Jesse Elias, MA; and Pamela M. Ling, MD, MPH In this video, Yogi Hale Hendlin, PhD; Jesse Elias, MA; and Pamela M. Ling, MD, MPH, offer additional insight into the article, "The Pharmaceuticalization of the Tobacco Industry." SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Is developing and legitimizing pharmaceutical-like, reduced-harm tobacco products giving the tobacco industry a new lease on life? Cigarettes constitute more than 90% of the industry's profits, and the number of smokers is increasing worldwide with population growth. Smoking prevalence is simultaneously declining, threatening cigarettes' long-term profitability. Transnational tobacco companies (TTCs) aggressively promote smoking in low- and middle-income countries but have also diversified their product lines to include more socially acceptable alternative nicotine products, marking an industry-wide shift (1, 2). This pursuit of new, standardized, designer, possibly government-certified nicotine products—a process we call pharmaceuticalization—may fundamentally change how policymakers and the public ...References1. Euromonitor International. Global tobacco key findings parts 1 and 2. Passport Database. 2016. Accessed at www.euromonitor.com/global-tobacco-key-findings-part-1-cigarettes-the-ongoing-quest-for-value/report on 20 June 2017. Google Scholar2. Philip Morris International. Assessing risk reduction. 2016. Accessed at www.pmi.com/eng/research_and_development/pages/assessing_risk_reduction_potential.aspx on 20 June 2017. Google Scholar3. Williams SJ, Martin P, Gabe J. The pharmaceuticalisation of society? A framework for analysis. Sociol Health Illn. 2011;33:710-25. [PMID: 21371048] doi:10.1111/j.1467-9566.2011.01320.x CrossrefMedlineGoogle Scholar4. World Health Organization. Guidelines for implementation of Article 5.3 of the WHO Framework Convention on Tobacco Control. 2008. Accessed at www.who.int/fctc/guidelines/adopted/article_5_3/en on 20 June 2017. Google Scholar5. Syqe Medical. The Syqe inhaler. 2016. Accessed at www.syqemedical.com on 20 June 2017. Google Scholar6. R.J. Reynolds. RJRT strategic review. 2008. Accessed at https://industrydocuments.library.ucsf.edu/tobacco/docs/sycm0222 on 20 June 2017. Google Scholar7. British American Tobacco. Proposed merger of British American Tobacco p.l.c. ("BAT") and Reynolds American Inc. ("Reynolds" or the "Company"). 2016. Accessed at www.rns-pdf.londonstockexchange.com/rns/1162N_-2016-10-20.pdf on 23 June 2017. Google Scholar8. Medicines and Healthcare products Regulatory Agency. Licensing Procedure for Electronic Cigarettes and Other Nicotine Containing Products (NCPs) as Medicines. London: Medicines and Healthcare products Regulatory Agency; 2017. Google Scholar9. Crowley RA; Health Public Policy Committee of the American College of Physicians. Electronic nicotine delivery systems: executive summary of a policy position paper from the American College of Physicians. Ann Intern Med. 2015;162:583-4. [PMID: 25894027]. doi:10.7326/M14-2481 LinkGoogle Scholar10. Food and Drug Administration; HHS. Clarification of when products made or derived from tobacco are regulated as drugs, devices, or combination products; amendments to regulations regarding "intended uses." Final rule. Fed Regist. 2017;82:2193-217. [PMID: 28071877] MedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From the University of California, San Francisco, San Francisco, California.Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Grant Support: By the National Cancer Institute at the National Institutes of Health (grants R01-CA141661 and R01-87472).Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M17-0759.Corresponding Author: Pamela M. Ling, MD, MPH, 530 Parnassus Avenue, Suite 366, University of California, San Francisco, San Francisco, CA 94143-1390; e-mail, pamela.[email protected]edu.Current Author Addresses: Drs. Hendlin and Ling and Mr. Elias: 530 Parnassus Avenue, Suite 366, University of California, San Francisco, San Francisco, CA 94143-1390.Author Contributions: Conception and design: Y.H. Hendlin, J. Elias, P.M. Ling.Analysis and interpretation of the data: Y.H. Hendlin, J. Elias, P.M. Ling.Drafting of the article: Y.H. Hendlin, J. Elias.Critical revision of the article for important intellectual content: Y.H. Hendlin, J. Elias, P.M. Ling.Final approval of the article: Y.H. Hendlin, J. Elias, P.M. Ling.Obtaining of funding: P.M. Ling.Administrative, technical, or logistic support: Y.H. Hendlin, J. Elias, P.M. Ling.Collection and assembly of data: Y.H. Hendlin, J. Elias.This article was published at Annals.org on 18 July 2017. PreviousarticleNextarticle Advertisement Annals Author Insight Video - Yogi Hale Hendlin, PhD; Jesse Elias, MA; and Pamela M. Ling, MD, MPH In this video, Yogi Hale Hendlin, PhD; Jesse Elias, MA; and Pamela M. Ling, MD, MPH, offer additional insight into the article, "The Pharmaceuticalization of the Tobacco Industry." FiguresReferencesRelatedDetails Metrics Cited byCommunication challenges of a tobacco addictiveness reduction policyBiochemistry of Desire: The Biosemiotics of Advertising to BacteriaCigarette smokers' concurrent use of smokeless tobacco: dual use patterns and nicotine exposureFactors Affecting Drug MetabolismLongitudinal transitions of cigarettes and electronic nicotine delivery systems among adolescents: Construction of a retrospective cohort using recall data from a cross-sectional sampleAssociation of alcohol and drug use with use of electronic cigarettes and heat-not-burn tobacco products among Korean adolescentsBreathe, breathe in the air, don't be afraid to careGambling control: in support of a public health response to gamblingIQOS labelling will mislead consumersInvisible smoke: third-party endorsement and the resurrection of heat-not-burn tobacco productsPhilip Morris International introduces new heat-not-burn product, IQOS, in South KoreaOrigins of tobacco harm reduction in the UK: the 'Product Modification Programme' (1972–1991)Public versus internal conceptions of addiction: An analysis of internal Philip Morris documentsThe Debate About Electronic Cigarettes: Harm Minimization or the Precautionary PrincipleRegulating Cannabis Manufacturing: Applying Public Health Best Practices from Tobacco Control 15 August 2017Volume 167, Issue 4Page: 278-280KeywordsBatsDrug regulationDrug therapyDrugsFood and Drug AdministrationMarijuanaNicotineNicotine replacement therapyPrevention, policy, and public healthTobacco control ePublished: 18 July 2017 Issue Published: 15 August 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Loading…
Stored only when both papers are in the corpus — 30 citations exist upstream.
Imported from OpenAlex (CC0) — nothing here is generated.